Search Results

Six-Month Data Published From Ablative Solutions’ Peregrine Postmarket Study

February 20, 2020—Ablative Solutions, Inc. announced that 6-month results from the Peregrine postmarket study were published by Professor Felix Mahfoud, MD, et al in Journal of the American College of Cardiology (JACC): Cardiovascular Interventions (2020;13:471–484).

ESC Issues Consensus Document on Catheter-Based Renal Denervation

April 25, 2013— The European Society of Cardiology (ESC) announced the publication of a European expert consensus document on catheter-based renal denervation.

Medtronic’s Global SYMPLICITY Registry Shows Sustained Lower Blood Pressure After Renal Denervation

June 25, 2020—Medtronic reported new data from the Global SYMPLICITY registry (GSR), which showed that renal denervation (RDN) with the Medtronic Symplicity RDN system significantly reduced blood pressure (BP) in uncontrolled hypertension patients out to 3 years independent of antihypertension medication burden.

ReCor’s Paradise Ultrasound Renal Denervation System Launched in Europe

October 6, 2021—ReCor Medical, Inc., a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., announced the commencement of the launch of the company’s Paradise ultrasound renal denervation system in Europe.

Inari PEERLESS II RCT Will Compare FlowTriever Versus Anticoagulation in PE Patients

May 22, 2023—Inari Medical, Inc. announced the planned enrollment of PEERLESS II, the company’s third randomized controlled trial (RCT) in venous thromboembolism (VTE).

Medtronic’s Symplicity Spyral RDN System Studied at 3 Years in SPYRAL HTN-ON MED Trial

April 4, 2022—Medtronic announced long-term data from the first 80 patients in the SPYRAL HTN-ON MED trial, which demonstrated that patients who were prescribed antihypertensive medications and treated with the company’s Symplicity Spyral renal denervation (RDN) system continued to show durable, clinically significant blood pressure reductions through 3 years.

EMBRACE to Study Medtronic’s Symplicity Spyral RDN System With Staged PCI

March 31, 2026—Medtronic announced it is supporting the investigator-initiated EMBRACE trial of the company’s Symplicity Spyral renal denervation (RDN).

Medtronic Presents Renal Denervation Data From Global SYMPLICITY Registry and Launches GSR-DEFINE Study

May 18, 2021—Medtronic announced that new clinical data from the Global SYMPLICITY Registry (GSR) indicating that renal denervation (RDN) with the company’s Symplicity system was associated with clinically significant and sustained blood pressure reductions in a real-world population of patients with hypertension (HTN) through 3 years.

Medtronic’s SPYRAL GEMINI Multiorgan Denervation Study Begins Enrollment

July 7, 2025—Medtronic announced that the first patient has been treated in its SPYRAL GEMINI global pilot study, which will investigate the safety and potential efficacy of multiorgan denervation (MDN) in patients with uncontrolled hypertension (HTN).

Medtronic’s Symplicity RDN System Assessed in 3-Year GSR DEFINE Data

May 23, 2023—Medtronic announced the findings from two studies supporting radiofrequency (RF) renal denervation (RDN) with the company’s Symplicity system for the treatment of patients with uncontrolled hypertension.

SoniVie Gains IDE Approval for THRIVE Pivotal Trial of Tivus RDN System

July 24, 2024—SoniVie announced that the FDA recently approved an investigational device exemption for the THRIVE pivotal study of the company’s Tivus therapeutic intravascular ultrasound system for renal denervation (RDN) therapy in patients with resistant hypertension.

Medtronic Announces Data From Global SYMPLICITY Registry

May 21, 2013—Medtronic, Inc. (Minneapolis, MN) announced the first results from the Global SYMPLICITY Registry, which reaffirmed the safety of the renal denervation procedure with the company's Symplicity renal denervation system in a real-world patient population.

Study Suggests That Local Tissue Anatomy May Explain Variable Patient Responses to RDN Therapy

May 4, 2015—CBSET, a not-for-profit preclinical research institute, announced that its scientists have published data and analyses that provide critical insights into the predictability, variability, and treatment success of catheter-based renal denervation (RDN) therapy.

Medtronic’s Symplicity Spyral RDN System Evaluated for Time-to-Target Range in SPYRAL HTN-ON MED and GSR-DEFINE

May 17, 2022—Medtronic announced data showing the benefits of the Symplicity blood pressure (BP) procedure with the company’s Symplicity Spyral renal denervation (RDN) system on achieving target BP level ranges.